Logo

Telix Spins Off Rhine Pharma to Broaden Global Radiopharmaceutical Reach

Share this
Telix

Telix Spins Off Rhine Pharma to Broaden Global Radiopharmaceutical Reach

Shots:

  • Telix Pharmaceuticals will spin off Rhine Pharma to make it an independent entity, broadening global reach to radiopharmaceuticals for cancer imaging & treatment using two isotopes, technetium-99m (Tc-99m) & rhenium-188 (Re-188)
  • Rhine Pharma was created under a collaboration between Telix and Heidelberg University Hospital for developing a PSMA-targeting small molecule labelled with 99mTc for SPECT imaging and 188Re for radioligand therapy
  • RHN001 was developed under the collaboration. Rhine Pharma is conducting P-I/IIa (RHINO) trial to assess the safety & efficacy of 99mTc-RHN001 for imaging & 188Re-RHN001 for therapy to treat advanced prostate cancer

Ref: Telix | Image: Telix

Related News:- Telix to Expand its US Operations Through the Acquisition of RLS Radiopharmacies

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions